New €23m EU Research Consortium To Accelerate Repurposing
The 24-Member Consortium Underscores EU Commitment to Advancing Repurposed Drugs
REMEDi4ALL is the latest in a series of European initiatives to develop and centralize drug repurposing R&D. The group will identify, test and validate new indications for existing medicines on top of shaping policies favorable to repurposing.
You may also be interested in...
Earlier industry involvement in repurposing activities and a more tailored European regulatory environment for value added medicines are among the proposals set out in a new report published by Medicines for Europe. The association has also suggested creating an “indications pool” to act as a central repository for repurposing information generated by not-for-profit and academic organizations through a STAMP pilot project.
Fresh from being named as the new president of Medicines for Europe, Medichem CEO Elisabeth Stampa sets out the association’s priorities around investment in European manufacturing, as well as identifying key obstacles that must be overcome to create a sustainable environment for off-patent medicines, in an exclusive interview with Generics Bulletin.
A new European initiative will offer scientific advice, fee waivers and other support to not-for-profit and academic sponsors to help them find new uses for existing medicines and hook up with commercial companies to seek marketing authorization.